Pricing Log in Create free account
Friday 6 November 2026 Export ATR’s income statement to Excel — free account

AptarGroup, Inc.

ATR Healthcare Medical Instruments & Supplies

AptarGroup, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.8 billion, up 5.42% from fiscal 2024.

Revenue
+6.03%
EPS
−73.9%
Free cash flow
−16.9%
Total debt
+14.6%

Quarter to September 2026, against a year earlier

143.84 3.02 −2.06%
Market cap
$9.1B
P/E
34.6×
Fwd P/E
25.9×
Dividend yield
1.00%
F-score
5/9
Altman Z
3.78
Beneish M
−2.48
Dividend safety
92/100
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Revenue by segment Fiscal 2025

  • Pharma
  • Beauty
  • Closures

Every year since 2009 →

Insider Decisions last twelve months

Sold, $m 8.11
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell 1 — 2 — — 2 2 — 4 1 — 1
Insider Ownership 2.08%

Capital & Financial Ratios $m

Size
Market Cap 9,130.00
Revenue ttm 3,991.23
Net income ttm 267.87
Free cash flow ttm 295.02
Net debt Q 1,163.12
Valuation
P/E 34.58
Forward P/E 25.90
Price / sales 2.29
Forward P/S Powerpack
Price / FCF 30.97
Price / book 3.47
Financial health
Current ratio Q 1.50 (at or above 1.5: strong)
Debt / equity Q 0.52
Interest coverage Q 8.55
Growth
Revenue growth Q +6.03% (above 0%: growing)
Operating income growth Q −1.40% (below 0%: shrinking)
EPS, this year −3.33% (below 0%: weak)
EPS, next year A +11.77%
Revenue, next year A +5.77%
EPS, past 5 yrs +12.91%
EPS, next 5 yrs A +6.15%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 2.6×, against a ten-year median of 2.6×; over the ten years it ranged from 2.1× in 2016 to 3.6× in 2021.
P/E against its own 10 years 84.89%
10-year low 10-year high
P/S against its own 10 years 41.22%
10-year low 10-year high
P/B against its own 10 years 14.52%
10-year low 10-year high
EV/Sales against its own 10 years 44.00%
10-year low 10-year high
EV/FCF against its own 10 years 50.79%
10-year low 10-year high

Dividends raised every year since 2017

Yield
1.00%
Annual rate
1.44
Payout ratio
35.0%
Growth, 2017–25
+4.57%/yr
  1. 1.28 ’17
  2. 1.32 ’18 +3
  3. 1.42 ’19 +8
  4. 1.44 ’20 +1
  5. 1.50 ’21 +4
  6. 1.52 ’22 +1
  7. 1.58 ’23 +4
  8. 1.72 ’24 +9
  9. 1.83 ’25 +6
  10. 1.95 ’26e +6
paid forecast change on the year, % Powerpack

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 224 226 410 212
Receivables 678 658 804 884
Inventory 513 462 538 583
Other — — — —
1,549 1,478 1,894 1,837
2023 2024 2025 Q'26
Payables 793 730 823 872
ST’ Debt 376 338 344 351
Other — — — —
1,251 1,068 1,166 1,223

Compound Annual Growth %

10y 5y 3y
Sales 5.01% 5.22% 4.37%
Cash Flow 5.82% (0.01%) 6.00%
Earnings 7.02% 12.91% 17.96%
Book Value 8.86% 7.73% 9.10%

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate 1.46 Actual 1.52

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q4 FY25 1.24 1.25 Beat by 0.01
Q1 FY26 1.15 1.19 Beat by 0.04
Q2 FY26 1.34 1.42 Beat by 0.08
Q3 FY26 1.46 1.52 Beat by 0.06
Q4 FY26 1.38 — Reports 4 February 2027

EPS $

Mar Jun Sep Dec Year
’26 1.12 1.36 0.51 — —
’25 1.17 1.67 1.92 1.13 5.89
’24 1.23 1.34 1.48 1.49 5.53
’23 0.82 1.24 1.26 0.93 4.25
’22 0.93 0.95 0.81 0.89 3.59
’21 1.24 0.81 0.70 0.85 3.61
’20 0.84 0.63 0.95 0.79 3.21
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 983 1,027 1,019 — —
’25 887 966 961 963 3,777
’24 915 910 909 848 3,583
’23 860 896 893 838 3,487
’22 845 845 837 796 3,322
’21 777 811 825 814 3,227
’20 722 699 759 749 2,929
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 119 103 168 — —
’25 83 126 178 184 570
’24 92 144 229 178 643
’23 98 84 173 220 575
’22 92 85 130 172 479
’21 72 103 84 104 363
’20 85 143 154 189 570
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 54 47 96 — —
’25 23 61 116 98 298
’24 17 76 149 108 351
’23 20 9 97 135 262
’22 19 10 46 87 163
’21 9 34 4 13 61
’20 20 86 102 116 323
Fiscal quarters ending in the months shown.

Valuation

The price implies free cash flow after share-based pay growing 15.2% a year for ten years. It grew 6.0% a year over the last ten.

Implied
15.2%
10 years, reported
6.0%
Open the model

Target Price Range

Analyst price targets

Recommendation Rating

1.8
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 2,331 2,469 2,765 2,860 2,929 3,227 3,322 3,487 3,583 3,777 3,991 +5.5% 3,995 4,109 4,351 +4.8%
Gross margin, % 35.81 35.08 34.43 36.41 37.09 35.84 35.03 36.23 37.83 37.19 35.79 +1.4 pt
EBT 280 295 266 342 301 322 335 375 470 491 361 +6.4%
EBT margin, % 12.03 11.94 9.62 11.96 10.28 9.97 10.07 10.75 13.11 13.01 9.04 +1.0 pt
Net income 206 220 195 242 214 244 240 284 374 392 268 +7.4%
Per share, $
Per share, $ Revenue 37.11 39.55 44.28 44.98 45.47 49.15 50.80 53.15 54.01 57.46 62.83 +5.0%
Earnings 3.27 3.52 3.12 3.81 3.32 3.72 3.66 4.34 5.65 5.97 4.16 +6.9%
Cash flow 5.18 5.20 5.02 8.09 8.85 5.54 7.32 8.77 9.70 8.67 9.03 +5.9%
Capex (2.07) (2.48) (3.32) (3.82) (3.83) (4.61) (4.82) (4.77) (4.41) (4.14) (4.38) +8.0%
Free cash flow 3.11 2.73 1.70 4.27 5.02 0.93 2.49 4.00 5.29 4.53 4.64 +4.3%
Book value 18.70 21.01 22.79 24.73 28.73 30.22 31.62 35.38 37.48 40.86 41.45 +9.1%
Shares, m 63 62 62 64 64 66 65 66 66 66 64 +0.5%
Valuation, ×
Valuation, × P/E 22.33 24.65 30.15 30.35 41.23 32.84 30.21 28.31 27.81 20.43 34.58 28.8
P/S 1.97 2.20 2.12 2.57 3.01 2.49 2.17 2.31 2.91 2.12 2.29 2.4
P/B 3.91 4.14 4.13 4.68 4.76 4.05 3.49 3.47 4.19 2.99 3.47 4.0
EV/Sales 2.10 2.42 2.46 2.89 3.29 2.78 2.48 2.55 3.13 2.41 2.58 2.7
EV/FCF 25.05 35.63 64.01 30.40 29.81 164.11 51.31 33.93 31.99 30.50 34.91 49.7
Cash, $m
Cash, $m Operating cash flow 325 325 314 514 570 363 479 575 643 570 573 +6.4%
Capex (130) (155) (207) (243) (247) (303) (316) (313) (293) (272) (278) +8.6%
Free cash flow 196 170 106 272 323 61 163 262 351 298 295 +4.8%
Balance, $m
Balance, $m Working capital 727 1,142 642 608 589 376 513 298 410 727 614 0.0%
Net debt 311 540 927 909 820 926 1,030 834 800 1,073 1,163 +14.8%
Shareholders’ equity 1,174 1,312 1,423 1,572 1,851 1,985 2,068 2,321 2,486 2,686 2,633 +9.6%
Returns, %
Returns, % ROA 8.15 7.66 5.98 6.98 5.67 6.00 5.74 6.57 8.43 8.11 5.23 0.0 pt
ROIC 13.20 10.91 7.61 9.36 7.94 7.46 7.65 8.00 9.44 8.33 7.83 (4.9) pt
ROE 17.69 17.70 14.24 16.17 12.51 12.73 11.81 12.96 15.58 15.19 9.86 (2.5) pt
People
People Employees 12,700 13,200 14,100 14,000 13,000 13,000 13,500 13,800 13,500 14,000 — +1.1%
Revenue/emp, $m 0.18 0.19 0.20 0.20 0.23 0.25 0.25 0.25 0.27 0.27 — +4.4%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026

Business profile

Updated

AptarGroup designs and manufactures devices and components that help dispense, deliver or protect medicines and consumer products. Founded in 1992 and headquartered in Crystal Lake, Illinois, the company is led by President and CEO Gael Touya.

For pharmaceutical customers, Aptar makes nasal spray pumps, inhaler valves and components used in injectable medicines. Its vial stoppers and syringe components sit in direct contact with drug products. It also sells materials designed to protect medicines and medical devices from moisture and other sources of degradation, as well as digital tools that help patients manage treatment and allow care teams to monitor them remotely.

Where the money comes from and where it goes Fiscal 2025

Fiscal 2025: revenue by segment, and margins
Pharma 1,738 46.03%
Beauty 1,338 35.43%
Closures 737 19.51%
Gross margin 37.19%
Operating margin 13.26%
Pre-tax margin 13.01%

Revenue by segment since 2009

AptarGroup, Inc. vs peers in Medical Instruments & Supplies (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
SOLV Solventum Corporation $14.8B 97.3× 47.7× −7.01% (below 0%: shrinking) n/m +561.90% (above 0%: growing) 0.00% 0.00% Compare
BAX Baxter International Inc. $13.3B — (loss-making) 21.3× +4.97% (above 0%: growing) n/m +255.56% (above 0%: growing) 33.40% 7.56% Compare
COO The Cooper Companies, Inc. $12.1B 21.7× 17.5× +0.56% (above 0%: growing) +357.14% (above 0%: growing) +65.96% (above 0%: growing) 66.77% 20.82% Compare
ALGN Align Technology, Inc. $11.3B 23.1× 20.4× +1.92% (above 0%: growing) +143.87% (above 0%: growing) +8.26% (above 0%: growing) 68.73% 16.67% Compare
RGEN Repligen Corporation $10.8B — (loss-making) — (loss-making) +10.86% (above 0%: growing) n/m −11.46% (below 0%: shrinking) 53.02% (14.12%) Compare
AVTR Avantor, Inc. $10.3B 30.3× 34.8× +4.59% (above 0%: growing) n/m −9.03% (below 0%: shrinking) 31.49% 8.21% Compare
ATR AptarGroup, Inc. $9.1B 34.6× 25.9× +6.03% (above 0%: growing) −73.85% (below 0%: shrinking) −16.86% (below 0%: shrinking) 36.59% 13.25%
BLCO Bausch + Lomb Corporation $7.1B — (loss-making) 749× +7.34% (above 0%: growing) n/m +182.54% (above 0%: growing) 64.65% 11.27% Compare
TFX Teleflex Incorporated $6.5B — (loss-making) 37.4× +28.88% (above 0%: growing) −17.33% (below 0%: shrinking) +220.14% (above 0%: growing) 58.16% 12.77% Compare
Median of peers $11.0B 26.7× 34.8× +4.78% +143.87% +124.25% 55.59% 9.74%

All 53 Medical Instruments & Supplies stocks →

From the latest earnings call

Updated

  • CFO Vanessa Kanu said Pharma core sales grew excluding emergency medicine, while lower sales of those high-margin products weighed on gross margin.
  • CEO Gael Touya said Aptar has a plan to address North American Beauty’s performance, but the transformation will take time.

Largest institutional holders 13F, quarter to 30 June 2026

Held by institutions 95.73%
Held by the ten largest 52.42%
Holder Shares Stake Change
Vanguard 7.04m 11.08% −114.96k
BlackRock 6.14m 9.65% +54.38k
State Farm 4.74m 7.46% 0.00
Morgan Stanley 3.52m 5.54% +148.11k
State Street 2.86m 4.50% +78.85k
Victory Capital 2.55m 4.02% +135.68k
Geode Capital Management 1.75m 2.75% +53.74k
Dimensional Fund Advisors 1.74m 2.74% +236.82k
Neuberger Berman 1.55m 2.44% +374.29k
FIDUCIARY MANAGEMENT INC /WI/ 1.42m 2.24% +171.43k
13F filings for the quarter to 30 June 2026: long positions in US-listed shares reported by managers with $100m or more, ~45 days after the quarter.

Pay and ownership Proxy statement filed 27 March 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 10.23m 661.78k 94.84
2024 9.93m 23.82m 120.66
2023 8.92m 12.93m 93.83
2022 8.84m 6.89m 82.38
2021 9.38m (2.79m) 90.46
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Read the proxy statement

AptarGroup, Inc. (ATR) Latest News

2 Nov

Impact 3 · · The Motley Fool

30 Oct

Impact 3 · · MarketBeat
Impact 3 · · Moby

29 Oct

Impact 4 · · Business Wire
Impact 3 · · Zacks
Impact 3 · · Associated Press
Impact 3 · · Business Wire

27 Oct

Impact 4 · · Business Wire

22 Oct

Impact 3 · · Business Wire

14 Oct

Impact 3 · · Business Wire

5 Oct

Impact 3 · · Zacks

22 Sep

Impact 4 · · Simply Wall St.

14 Sep

Impact 3 ·

5 Aug

Impact 3 ·

3 Aug

Impact 3 ·

31 Jul

Impact 4 ·
Impact 3 · · MarketBeat transcript
Impact 3 · · Moby transcript

30 Jul

Impact 3 ·

20 Jul

Impact 3 ·

9 May

Impact 4 · · MarketBeat

6 May

Impact 4 · · Business Wire
Impact 3 · · Zacks

3 May

Impact 4 · · Simply Wall St.

2 May

Impact 3 · · GuruFocus.com
Impact 3 ·

1 May

Impact 4 · · Moby
Impact 3 · · MarketBeat

30 Apr

Impact 4 · · Business Wire
Impact 3 · · Zacks

ATR metrics, ten years each

stockrow.com/ATR · Data as of Nov 5, 2026 · For information only; not investment advice. · © 2026 stockrow.com